The influence of comorbidities on achieving an N-terminal pro-b-type natriuretic peptide target: a secondary analysis of the GUIDE-IT trial,ESC Heart Failure

当前位置： X-MOL 学术 › Esc Heart Fail. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

The influence of comorbidities on achieving an N-terminal pro-b-type natriuretic peptide target: a secondary analysis of the GUIDE-IT trial
ESC Heart Failure ( IF 3.8 ) Pub Date : 2021-11-16 , DOI: 10.1002/ehf2.13692
Justin A Ezekowitz ₁ , Wendimagegn Alemayehu ₁ , Sarah Rathwell ₂ , Andrew D Grant ₃ , Mona Fiuzat ₄ , David J Whellan ₅ , Tariq Ahmad ₆ , Kirkwood Adams ₇ , Ileana L Piña ₈ , Lawton S Cooper ₉ , James L Januzzi ₁₀ , Eric S Leifer ₉ , Daniel Mark ₄ , Christopher M O'Connor ₁₁ , G Michael Felker ₄

Affiliation

Canadian VIGOUR Centre, University of Alberta, Edmonton, AB, Canada.
Women and Children's Health Research Institute, University of Alberta, Edmonton, AB, Canada.
Department of Cardiac Sciences, Cumming School of Medicine, University of Calgary, and the Libin Institute of Cardiovascular Research, Calgary, AB, Canada.
Division of Cardiology, Duke University School of Medicine, Durham, NC, USA.
Department of Medicine, Thomas Jefferson University, Philadelphia, PA, USA.
Section of Cardiovascular Medicine, Yale School of Medicine, New Haven, CT, USA.
Division of Cardiology, University of North Carolina, Chapel Hill, NC, USA.
School of Medicine, Wayne State University, Detroit, MI, USA.
National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA.
Massachusetts General Hospital Harvard Medical School, and Baim Institute for Clinical Research, Boston, MA, USA.
Inova Heart and Vascular Institute, Falls Church, VA, USA.

N-terminal pro-b-type natriuretic peptide (NT-proBNP) values may be influenced by patient factors beyond the severity of illness, including atrial fibrillation (AF), renal dysfunction, or increased body mass index (BMI). We hypothesized that these factors may influence the achievement of NT-proBNP targets and clinical outcomes.

中文翻译：

合并症对实现 N 端 pro-b 型利钠肽靶点的影响：GUIDE-IT 试验的二次分析

N 末端前-b 型利钠肽 (NT-proBNP) 值可能受疾病严重程度以外的患者因素影响，包括心房颤动 (AF)、肾功能不全或体重指数 (BMI) 增加。我们假设这些因素可能会影响 NT-proBNP 目标的实现和临床结果。

更新日期：2021-11-16

点击分享查看原文

点击收藏

公开下载

阅读更多本刊最新论文

全部期刊列表>>